Today's picks
Top candidates from last night's scan. Scores refresh each evening; prices are live.
Top candidates from last night's scan. Scores refresh each evening; prices are live.
On today's picks · Score 100/100 · Strong candidate
View all picks →GSK PLC ORD 31 1/4P
£1,983.00
Passed rules
26
Failed rules
0
Opportunity
0.87:1 R:R
Data confidence
high
Main reason
Strong quality (8/8) and technical alignment with limited red flags.
Conviction
Quality 35/35 (8/8 passed)
Technical 40/40 (8/8 passed)
Trade setup 15/15 (4/4 passed)
Red flags 10/10 (0/6 triggered — informational, gates only)
Conviction total 100/100 — quality + technical + trade setup only. Unknown rules count as not passed.
Opportunity
Status: Known upside
Technical target: £2,011.00
Analyst target: £2,086.90
Effective target: £2,011.00
R:R 0.87:1
Analyst target aligns with or is below technical upside.
Trade levels
Entry: £1,983.00
Stop loss: £1,950.67
Effective target: £2,011.00
Notes
Company is profitable
Profit margin is 17.8%.
Revenue is growing
Revenue growth is 1.5%.
EPS / earnings are growing
Earnings growth is 8.4%.
Free cash flow is positive
Free cash flow is positive.
Debt is manageable
Debt-to-equity is 109.7% (manageable).
Return on equity or capital is positive
ROE 40.9%, ROA 10.0%.
Market cap is not tiny / speculative
Market cap is $79.5B.
Valuation is not extreme
P/E 14.0, P/S 2.4.
Price above 50-day moving average
Price $1983.00 is above 50-day MA $1930.93.
Price above 200-day moving average
Price is above 200-day MA $1894.45.
Last 2 evening scans when GSK.L was analyzed
Sat 27 Jun27 Jun 2026
£1,983.00
Strong quality (8/8) and technical alignment with limited red flags.
Fri 26 Jun26 Jun 2026
£1,983.00
Strong quality (8/8) and technical alignment with limited red flags.
News, company info, and filings from Yahoo Finance.
Healthcare · Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Rule-based analysis generated by Huntover. Not financial advice.
50-day MA above 200-day MA
50-day MA is above 200-day MA (bullish alignment).
Price near 52-week high
Within 13.1% of 52-week high.
Price not near 52-week low
53.9% above 52-week low.
Stock is in an uptrend
Price up 5.4% over 20 days.
Recent volume above average
Volume is 1.78x the average.
Breaking above recent resistance
Price near/above recent resistance $2011.00.
Clear entry price exists
Current price $1983.00 can be used as entry reference.
Stop loss no more than 10% below entry
Suggested stop at $1950.67 (1.6% below entry).
Spread / liquidity risk acceptable
Average daily volume is 7.76M.
No earnings within 7 days
Next earnings in 30 days.
Very high debt
Debt level is not extreme.
Price near 52-week low
Not near 52-week low.
Very low trading volume
Volume is not unusually low.
Recent large price drop
No recent large drop detected.
Extreme valuation
Valuation is not extreme.
Missing too much data
0 data field(s) missing.
No rules failed.
All rules had enough data.
MT Newswires · 24 Jun 2026
Zacks · 25 Jun 2026
Insider Monkey · 24 Jun 2026
GSK Announces Tender Offer To Acquire Nuvalent
24 Jun 2026